AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01086930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReJoyce Workstation
Description: The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
Study NCT04018729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zephyr Endobronchial Valve
Description: Endoscopic lung volume reduction therapy.
Study NCT02576197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
Study NCT02576197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
Study NCT04520230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid
Description: inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
Study NCT04520230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg capsule inhaled once daily + Budesonide
Description: inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
Study NCT04520230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Tiotropium
Description: long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
Study NCT01198691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insorb absorbable staples
Description: Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
Study NCT01198691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb
Description: Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
Study NCT04367389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
Study NCT04367389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
Study NCT03129997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten test food
Description: Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
Study NCT03129997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten test food
Description: Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
Study NCT03295942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-336B11
Description: OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
Study NCT04018729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Marrow-derived mesenchymal stromal cell
Description: Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
Study NCT00903045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride
Description: Propiverine hydrochloride 20mg twice a day
Study NCT00903045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo twice a day
Study NCT02695888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risky Driving Prevention
Description: The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
Study NCT02695888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Healthy Living
Description: The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
Study NCT02254460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test
Description: Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
Study NCT02254460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
Study NCT04764019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution intestinal manometry
Description: Evaluation of intestinal manometry by the use a high resolution intestinal manometry catheter with 34 closely spaced sensors.
Study NCT02043301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the upper arm
Study NCT01642407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Study NCT01558193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance
Study NCT02043301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615; RN316)
Description: Single 150 mg PF-04950615 dose administered SC to the thigh
Study NCT04529551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601A
Description: A filtered, king size cigarette with a menthol capsule in the filter.
Study NCT04529551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1601B
Description: A filtered, king size cigarette with a menthol capsule in the filter.
Study NCT03851276 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Multi-sliced computed tomography (MSCT)
Description: Surgery planning done based solely on MSCT.
Study NCT01133210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
Study NCT01133210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
Study NCT01558193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-vitamin/mineral
Description: Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
Study NCT06142305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DDH surgery and casting
Description: DDH surgery and casting
Study NCT02093520 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MILD Procedure
Description: The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
Study NCT02093520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Injection of epidural steroids into the lumbar spine
Study NCT04369612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard post-transplant follow-up
Study NCT04369612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based monitoring
Description: Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
Study NCT01558193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Docosahexaenoic acid
Description: 22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
Study NCT01558193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA plus vitamins/minerals
Description: The DHA and vitamin/mineral supplements are as above
Study NCT02640469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine with water rinse
Description: This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute
Study NCT02640469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine without water rinse
Description: Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo omalizumab
Description: The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo omalizumab
Description: The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed rush immunotherapy (RIT)
Description: RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ragweed rush immunotherapy (RIT)
Description: RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo rush immunotherapy (RIT)
Description: The placebo for rush immunotherapy will contain the diluents and histamine.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rush immunotherapy (RIT)
Description: The placebo for rush immunotherapy will contain the diluents and histamine.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed immunotherapy (IT)
Description: Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ragweed immunotherapy (IT)
Description: Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo immunotherapy (IT)
Description: The placebo for immunotherapy will contain the diluents and histamine.
Study NCT00078195 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo immunotherapy (IT)
Description: The placebo for immunotherapy will contain the diluents and histamine.
Study NCT01149460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Test 1000 mg Tablet
Study NCT01149460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Reference Listed Valacyclovir 1000 mg Tablet
Study NCT01531036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Ultrasound elastography by means of shear wave propagation into breast tissue
Description: Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
Study NCT02640131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Component
Description: Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
Study NCT02640469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine + sterillium hand rub
Description: Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
Study NCT02448810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + infusional 5-FU/LV
Description: Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection
Study NCT02448810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + panitumumab
Description: Study Part 1: Safety Run-in~* Administered weekly as part of a 4 week treatment cycle~* Intravenous injection
Study NCT02448810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + 5-FU/LV
Description: Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection
Study NCT02448810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX69 + panitumumab
Description: Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection
Study NCT02448810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Investigator's choice~* Dose according to drug label
Study NCT02448810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: * Investigator's choice~* Dose according to drug label~* Choice includes panitumumab in KRAS \&NRAS wt group only
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 1
Description: Participants receive routine care outside the bounds of the trial. No further work-up.
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health and Quality of Life questionnaire
Description: Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up or treatment.
Description: Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 2
Description: Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical follow-up 3
Description: Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
Study NCT03327597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical follow-up control
Description: Control clinical visit
Study NCT02883842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
Study NCT01268150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
Study NCT03276793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Patients will undergo an MRI scan
Study NCT02640131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomedical Component
Description: Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
Study NCT02640131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Component
Description: Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
Study NCT02640131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
Study NCT03757117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy
Description: Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily
Study NCT03757117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation
Description: Transgender women community peer navigation
Study NCT01808170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cystectomy
Description: will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.